What is the typical clinical course of rhinovirus and enterovirus infections?

Clinical Course of Rhinovirus and Enterovirus Infections

Rhinovirus and enterovirus infections typically follow a self-limited course lasting 7-14 days in immunocompetent individuals, with symptoms peaking within 3 days and gradually resolving, though these viruses can cause severe disease requiring intensive care in young children, immunocompromised patients, and those with underlying chronic conditions.

Typical Clinical Timeline

Incubation and Symptom Onset

The incubation period for rhinovirus is approximately 1.9 days (95% CI, 1.4-2.4) 1. In adults with rhinovirus infections, the median duration is 11 days, with symptoms typically peaking within the first 3 days then gradually declining 1, 2.

Symptom Progression Pattern

• First symptom: Most commonly sore throat (40% of cases) 2
• Peak symptoms: Within 3 days of onset 1
• Resolution: Symptoms gradually decline and resolve within 10-14 days 1
• Nasal purulence: Discolored discharge is related to neutrophil presence, not bacterial infection, and represents inflammation rather than secondary bacterial infection 1

Clinical Manifestations by Population

Immunocompetent Adults and Children

Enteroviruses are most commonly self-limiting febrile illnesses in infants and young children 3. The typical presentation includes:

• Upper respiratory tract symptoms (rhinorrhea, postnasal drip, cough)
• Nasal congestion and obstruction
• Occasional tracheobronchitis 4
• Asymptomatic infection occurs in approximately 13% of cases 4

Severe Disease Presentations

While most infections are mild, certain populations experience more severe courses:

Pediatric Intensive Care Cases 5:

• 42.67% present with bronchopneumonia/pneumonia
• 32% present with acute bronchiolitis/bronchitis
• 9.33% present with sepsis/septic shock
• 6.67% develop pediatric acute respiratory distress syndrome
• Overall mortality remains low at 1-1.3%

High-Risk Features for Severe Disease 6: Children with rhinovirus/enterovirus infections requiring hospitalization have:

• Significantly higher rates of underlying immunosuppressive conditions (37.9%)
• Increased odds of hospitalization compared to RSV (OR 2.6; 95% CI 1.4-4.8)
• Increased odds of severe clinical disease compared to influenza (OR 3.0; 95% CI 1.6-5.6)

Immunocompromised Patients

In hematopoietic stem cell transplant (HSCT) recipients 4:

• Detection rates reach up to 40% among symptomatic patients
• Prolonged viral shedding over 4 weeks is frequent
• Lower respiratory tract disease with pneumonia occurs in <10% of allogeneic HSCT patients
• Estimated mortality <10% when pneumonia develops
• Coinfections with other respiratory viruses occur in 19% of patients

Specific Enterovirus Complications

Neurological Manifestations

Enteroviruses are now recognized as the most common cause of meningitis 3. Severe neurological disease includes:

• Meningoencephalitis
• Myelitis and paralysis
• Acute flaccid myelitis (AFM) - characterized by rapid limb weakness with gray matter changes on MRI 3
• Rhomboencephalitis (particularly with EV-A71)

Other Severe Manifestations 3:

• Myocarditis
• Sepsis-like syndrome
• Acute hepatitis
• Respiratory disease (particularly EV-D68)

Viral Coinfections and Clinical Impact

Coinfections significantly modify clinical course 7:

• Patients with single rhinovirus/enterovirus detection required invasive mechanical ventilation as frequently as those with RSV codetection
• Multiple viral codetections may result in reduced clinical severity - none required invasive mechanical ventilation 7
• Children aged 0-15 years have 7 times higher probability of coinfection with other respiratory viruses (OR 6.887; 95% CI 3.928-12.045) 8

Age-Specific Considerations

Young Children (0-15 years) 8:

• 1.5 times higher probability of rhinovirus/enterovirus infection (OR 1.496; 95% CI 1.147-1.952)
• Most severe cases occur in children <5 years (74.5% of pandemic-era detections)
• Higher lymphocyte and liver enzyme levels in 1-24 month age group 5

Older Children and Adults (>24 months) 5:

• Higher hemoglobin and kidney function test levels
• Different clinical presentation patterns

Chronic Disease Exacerbations

Rhinovirus/enterovirus infections are associated with 8:

• Higher risk of asthma exacerbation (OR 2.545; 95% CI 1.336-4.851)
• Increased COPD exacerbation risk (OR 1.781; 95% CI 1.022-3.103)
• Lower probability of bronchiolitis compared to other viruses (OR 0.236; 95% CI 0.117-0.474)

Respiratory Support Requirements

In pediatric intensive care settings 5:

• 65.3% require continuous oxygen therapy
• 33.3% require noninvasive ventilation
• 32% require high-flow nasal cannula oxygen therapy
• 16% require invasive mechanical ventilation

Key Clinical Pitfalls

1. Do not assume bacterial infection based on purulent nasal discharge alone - discoloration reflects neutrophil presence from inflammation, not bacterial superinfection 1

2. Distinguish viral rhinosinusitis from bacterial rhinosinusitis: Bacterial infection should only be suspected when symptoms persist ≥10 days without improvement, worsen after initial improvement ("double sickening"), or present with severe features (fever >38.3°C with severe pain) 9, 10, 11

3. Recognize that rhinovirus/enterovirus can cause severe disease - these are not always benign "common cold" viruses, particularly in immunocompromised patients and young children with comorbidities 6

4. Prolonged viral shedding does not indicate ongoing active disease - detectability can persist for 2-3 weeks or longer, especially in immunocompromised patients 4

5. EV-D68 requires special consideration - it is rarely detectable in CSF or stool samples and is associated with severe respiratory disease and acute flaccid paralysis, requiring respiratory specimen testing 3, 12